

Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice

著者	Kato Sayaka, Kato Yukio, Nakamura Tadakatsu, Sugiura Tomoko, Kubo Yoshiyuki, Deguchi Yoshiharu, Tsuji Akira
journal or publication title	Biopharmaceutics and Drug Disposition
volume	30
number	9
page range	495-507
year	2009-10-01
URL	http://hdl.handle.net/2297/20401

doi: 10.1002/bdd.681

**Genetic deficiency of carnitine/organic cation transporter 2 (*slc22a5*)
is associated with altered tissue distribution of its substrate
pyrilamine in mice**

Sayaka Kato, Yukio Kato, Tadakatsu Nakamura, Tomoko Sugiura, Yoshiyuki Kubo,

Yoshiharu Deguchi and Akira Tsuji

Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology,
Kanazawa University, Kakuma-machi, Kanazawa 920-1192 (S.K., Y.K., T.N., T.S., Y.K., A.T.)
and Department of Drug Disposition and Pharmacokinetics, School of Pharmaceutical Sciences,
Teikyo University, 1091-1 Suarashi, Sagamiko, Sagamihara, Kanagawa 229-0195 (Y.D.), Japan.

This study was supported in part by a Grant-in-Aid for Scientific Research provided by the
Ministry of Education, Science and Culture of Japan.

RUNNING TITLE: Genetic deficiency of *octn2* affects pyrrolamine disposition

Corresponding author :

Prof. Akira Tsuji, Ph.D

Division of Pharmaceutical Sciences, Graduate School of Natural Science and
Technology, Kanazawa University, Kakuma, Kanazawa 920-1192, Japan

Tel:(81)-76-234-5085 / Fax:(81)-76-264-4010

Email: tsuji@kenroku.kanazawa-u.ac.jp

ABSTRACT

Carnitine/organic cation transporter 2 (OCTN2) recognizes various cationic compounds as substrates *in vitro*, but information on its pharmacokinetic role *in vivo* is quite limited. Here we demonstrate altered tissue distribution of the OCTN2 substrate pyrilamine in juvenile visceral steatosis (*jvs*) mice, which have a hereditary defect of the *octn2* gene. At 30 min after intravenous injection of pyrilamine, the tissue-to-plasma concentration ratio (K_p) in heart and pancreas was higher, whereas the K_p in kidney and testis was lower in *jvs* mice compared with wild-type mice. Pylamine transport studies in isolated heart slices confirmed higher accumulation, together with lower efflux, of pyrilamine in heart of *jvs* mice. The higher accumulation in heart slices of *jvs* mice was abolished by lowering the temperature, by increasing the substrate concentration, and in the presence of other H_1 antagonists or another OCTN2 substrate, carnitine, suggesting that OCTN2 extrudes pyrilamine from heart tissue. On the other hand, the lower distribution to the kidney of *jvs* mice was probably due to down-regulation of a basolateral transporter coupled with OCTN2, because, in *jvs* mice, (i) K_p in kidney of pyrilamine assessed immediately after intravenous injection (~ 1 min) was also lower, (ii) urinary excretion of pyrilamine was lower, and (iii) uptake of pyrilamine in kidney slices was lower. The renal uptake of pyrilamine was saturable (K_m ~236 μM) and was strongly inhibited by cyproheptadine, astemizole, ebastine and

terfenadine. The present study thus indicates that genetic deficiency of *octn2* alters pyrilamine disposition tissue-dependently.

KEY WORDS: pharmacokinetics, pyrilamine, octn2, heart, kidney

INTRODUCTION

Carnitine/organic cation transporter 2 (OCTN2/SLC22A5) was first isolated as a novel transporter with high homology to OCTN1/SLC22A4 [1,2]. The endogenous substrate of OCTN2 is a vitamin-like compound, carnitine, and deficiency of the *OCTN2* gene leads to systematic carnitine deficiency (SCD) [3]. Carnitine is water-soluble, not membrane-permeable, and is required for β -oxidation of fatty acids. In mammals, carnitine is supplied both by biosynthesis and from food intake.

Juvenile visceral steatosis (*jvs*) mouse, which has a mutation in the *octn2* gene (Leu352Arg), was found to exhibit SCD-like symptoms, such as cardiac hypertrophy, lipid accumulation in the liver and hyperammonemia [3-6]. Several pharmacokinetic studies using *jvs* mice have revealed that OCTN2 governs carnitine disposition *in vivo*: ingested carnitine is absorbed in the small intestine via OCTN2, moved to circulating blood, and taken up by the liver and other organs via OCTN2 [7-9]. Because of its limited plasma protein binding, carnitine is easily filtered in the glomerulus, but is efficiently reabsorbed in the kidney via OCTN2 [7]. The putative role of OCTN2 in carnitine homeostasis is consistent with the localization of OCTN2 on apical membranes of epithelial cells in the small intestine and kidney [9,10].

OCTN2 has also been reported to be involved in renal tubular secretion of tetraethylammonium (TEA), another OCTN2 substrate [11]. In addition to carnitine and TEA,

OCTN2 also transports various cationic compounds including pyrilamine, quinidine and verapamil [12-14]. However, identification of OCTN2 substrates has been performed using OCTN2-transfected cell line systems *in vitro*, and the pharmacokinetic role of OCTN2 *in vivo* has still not been fully elucidated. Recently, Grigat *et al.* presented *in vitro* evidence that OCTN2 efficiently transports mildronate, though they considered that it is not a general drug transporter [15]. On the other hand, we have recently found that OCTN2 plays a major role in renal secretion of a β -lactam antibiotic, cephaloridine, using *jvs* mice [16].

Among OCTN2 substrates, pyrilamine is a member of the first-generation H₁ antagonists, some of which, such as diphenhydramine and hydroxyzine, are widely used to treat allergic rhinitis and urticaria, despite their sedative side effect. The sedation is caused by their efficient distribution to the brain. In contrast to the first-generation compounds, second-generation H₁ antihistamines cause less somnolence. In connection with this, transport mechanisms of antihistamines to the brain have been widely studied. One of the major transporters involved in the brain distribution of H₁ antihistamines is P-glycoprotein (P-gp), the function of which as a drug efflux pump at the blood brain barrier (BBB) was originally clarified by Tsuji *et al.* using bovine primary cultured brain capillary endothelial cells [17], and subsequently confirmed in *mdr1a* gene knockout mice [18]. The permeability at the BBB of the nonsedative H₁-antagonist ebastine and its metabolite carebastine was restricted by P-gp [19].

Chen *et al.* have also shown that P-gp reduces the brain's exposure to non-sedating second-generation, but not sedating first-generation, H₁ antihistamines [20].

Other side effects provoked by certain H₁ antagonists include cardiovascular toxicity. In particular, astemizole and terfenadine block rapid delayed rectifier K⁺ current, leading to serious adverse events, such as QT prolongation [21, 22]. Occurrence of this side effect depends on the affinity of drug for the K⁺ channel and on the drug concentration in cardiomyocytes. Therefore, it is necessary not only to clarify the interaction of drugs with the K⁺ channel, but also to elucidate the membrane permeation mechanism of these drugs in the heart, since the latter may influence the unbound concentration of the drugs inside cardiomyocytes. However, only limited information is available on transporter functions in cardiomyocytes. Recently, Iwata *et al.* have proposed that OCTN2 is localized on the sarcolemma of cardiomyocytes and on the membrane in the intercalated disc, and suggested that it is involved in the influx of carnitine into the heart [23]. In the present study, we aimed to examine the possible involvement of OCTN2 in the distribution of pyrilamine to the heart and other organs, using *jvs* mice as a tool to clarify the role of OCTN2 *in vivo*.

MATERIALS AND METHODS

Materials and animals

Pyrilamine was purchased from Sigma-Aldrich Japan K.K. (Tokyo, Japan). All other reagents were commercial products of reagent grade. *Jvs* mice, originally found among mice of the C3H.OH strain [24], and control (wild-type) C3H/HeJ mice (Japan SLC, Hamamatsu, Japan) were used. By mating heterozygous male and female mice, we obtained homozygous mutants (*jvs/jvs*) and wild-type mice. All the animal experiments were performed according to the Guidelines for the Care and Use of Laboratory Animals in Takara-machi Campus of Kanazawa University.

Pharmacokinetic studies of pyrilamine *in vivo*

Eight-week-old male mice were used after overnight starvation to study the disposition of pyrilamine. Mice were anesthetized with pentobarbital and injected with 3.75 mg/kg of pyrilamine via the right jugular vein as a bolus. Serial blood samples (20 μ L) were collected at designated time intervals from the right jugular vein of each mouse using heparinized capillary tubes. Urine samples were collected at designated times by washing the bladder with saline through polyethylene tubing (SP31, Natsume, Tokyo, Japan). For determination of tissue-to-plasma concentration ratio (K_p), the mice were decapitated at 1 or 30 min after the

intravenous injection. Tissues were quickly excised, rinsed well with ice-cold saline, blotted to dryness, weighed and stored at -30°C until use.

Uptake studies of pyrilamine in isolated heart and kidney slices

Mice were sacrificed by decapitation under diethyl ether anesthesia. The heart and kidney were immediately excised and rinsed with about 50 mL of ice-cold saline. Atrium and connective tissues were carefully removed, and the heart was sectioned at 350 μm with a microslicer (DTK-2000, Dosaka EM Co. Ltd., Kyoto, Japan). The kidney was sectioned by the same method. The slices were then soaked in ice-cold Krebs-Ringer bicarbonate buffer (KRB buffer) containing 115 mM NaCl, 4.7 mM KCl, 1.1 mM MgCl₂, 2.0 mM KH₂PO₄, 25 mM NaHCO₃, 2.5 mM CaCl₂ and 11 mM D-glucose. After 5 min pre-incubation, the heart and kidney slices were moved to KRB buffer containing 2 μM pyrilamine prewarmed at 37°C, with bubbling of 95% O₂/5% CO₂. This pyrilamine concentration (2 μM) was set to be as lower as possible to avoid any saturation in transport systems, but also to be higher enough for the determination of pyrilamine in both tissue slices and medium using HPLC. At designated times, slices were picked up from the incubation buffer and rinsed with about 50 mL of ice-cold saline. They were blotted dry, weighed and stored at -30°C until use.

In the inhibition experiments, inhibitors were also included in the KRB buffer. In the

efflux experiments, the heart slices were first incubated in KRB buffer containing 2 μM pyrilamine for 60 min, washed with ice-cold KRB buffer and then moved to KRB buffer prewarmed at 37°C. At designated times, the slices were removed, washed with ice-cold KRB buffer, blotted dry, weighed and stored at -30°C until the HPLC determination. Efflux transport activity was evaluated by measuring the pyrilamine content remained in the slices.

All the uptake values were expressed as slice-to-medium concentration (S/M) ratio per unit tissue weight ($\mu\text{L}/\text{mg}$ tissue), obtained by dividing the amount of pyrilamine in the slices by the initial concentration in the medium and the weight of the slices.

Measurement of blood-to-plasma concentration ratio and plasma protein binding

Blood was taken from mice under pentobarbital anesthesia into heparinized tubes. A 500 μL aliquot of blood was pre-incubated for 3 min at 37°C, and then spiked with 10 μL of drug solution. The mixture was incubated at 37°C for 30 min, and an aliquot was taken for determination of blood concentration (C_b). The plasma was separated by centrifugation of the residual mixture at 2,500 g at 20°C for 10 min. An aliquot of plasma was then taken for the determination of total plasma concentration (C_p). The remaining plasma was placed in an ultrafiltration apparatus (Centrifree, Amicon Inc., Beverly, MA) with a molecular mass cut-off of 13 kD and centrifuged at 3,000 rpm (TOMY RL-100, Tokyo, Japan) for 10 min. After

centrifugation, the concentration in the filtrate was determined as unbound concentration (C_u).

The blood-to-plasma concentration ratio (R_b) was calculated by dividing C_b by C_p . The free fraction of pyrilamine in plasma (f_p) was calculated by dividing C_u by C_p . All the binding was normalized with respect to the filter blank.

Determination of pyrilamine

The homogenized tissue samples, blood, plasma and urine were deproteinized with methanol and centrifuged at 10,000 g for 15 min. The supernatant was subjected to HPLC. The HPLC analysis for pyrilamine was performed using COSMOSIL 5C₁₈-MS-II (150 x 4.6 mm) (Nacalai Tesque, Kyoto, Japan). The mobile phase consisted of methanol/10 mM formate buffer (pH 3.75) (33/67). The UV detector was operated at a wavelength of 244 nm. Chlorpheniramine was used as an internal standard.

Data analysis

Kinetic parameters for uptake by tissue slices were obtained using nonlinear least-squares regression analysis [25] based on the following equation:

$$v = \frac{V_{\max} \times s}{K_m + s} + K_{ns} \times s$$

where v , s , V_{\max} , K_m , and K_{ns} represent the initial uptake velocity, substrate concentration, maximum uptake velocity, Michaelis constant and non-saturable uptake clearance, respectively.

The selection of the equation was based on Akaike's Information Criterion.

Statistical analysis

Statistical analyses were performed by means of Student's *t*-test or ANOVA with Tukey's post hoc comparison test for single and multiple comparisons, respectively. Differences were considered statistically significant at $p < 0.05$.

RESULTS

Plasma concentration, urinary excretion and tissue distribution of pyrilamine in wild-type and *jvs* mice

After intravenous injection of pyrilamine, little difference was observed in plasma concentration profile between wild-type and *jvs* mice (Fig. 1a). Urinary excretion of pyrilamine in *jvs* mice was lower than that in wild-type mice (Fig. 1b). The fraction of the dose excreted into urine during 240 min after the injection was at most 2-6% (Fig. 1b). It has been reported that 30-40% of the dose was recovered in urine following i.v. administration of [¹⁴C]pyrilamine within 24 hr, predominantly as a glucuronide metabolite, whereas urinary excretion of unchanged pyrilamine was less than 10% in rats [26]. The present study also indicated that renal excretion would be a minor elimination pathway for pyrilamine in mice (Fig. 1b). Due to quantification limit for pyrilamine by HPLC system in the present study, time course of plasma pyrilamine concentration could be chased until 120 min (Fig. 1a), and this was the reason for inconsistent time periods between plasma concentration and urinary excretion profiles (Fig. 1a, 1b).

On the other hand, at 30 min after intravenous injection, the K_p of pyrilamine in heart and pancreas was 1.8 and 1.5 times larger, respectively, in *jvs* mice compared with wild-type mice (Table 1). The K_p in the small intestine of *jvs* mice was also 3.8-fold higher than that in

wild-type mice, although this difference was not statistically significant. The K_p values in kidney and testis of *jvs* mice, on the other hand, were about 15 and 65% of those in wild-type mice (Table 1). Thus, the change in distribution of pyrilamine in *jvs* mice was tissue-dependent. The K_p values were also determined at 1 min after intravenous injection, and that in kidney of *jvs* mice was again significantly lower than that in wild-type mice (Table 1). The K_p at 1 min after injection in heart of *jvs* mice tended to be higher than that in wild-type mice, although this difference was not significant (Table 1). The values for plasma unbound fraction (f_p) of pyrilamine in wild-type and *jvs* mice were 0.685 ± 0.093 and 0.513 ± 0.093 , whereas the values for blood-to-plasma concentration ratio (R_b) were 1.66 ± 0.11 and 1.74 ± 0.23 , respectively, showing no significant difference between the two strains.

Influx and efflux of pyrilamine in isolated heart slices

The difference in heart distribution between wild-type and *jvs* mice may be explained by differences in tissue binding, influx and/or efflux processes. To investigate the transport mechanism in detail, uptake studies using heart slices were performed. Accumulation of pyrilamine in heart slices at 10 min was similar in wild-type and *jvs* mice, whereas after 60 min, that in *jvs* mice was higher than that in wild-type mice (Fig. 2a). In addition, pyrilamine content remaining in the heart slices was determined after 60 min preincubation with pyrilamine in order

to directly examine the efflux process from the heart. The amount of pyrilamine that remained in the heart slices of *jvs* mice was higher than that in heart slices of wild-type mice (Fig. 2b), suggesting that there is a difference in the efflux process between wild-type and *jvs* mice.

The larger accumulation (Fig. 2a) and lower efflux (Fig. 2b) in the heart slices of *jvs* mice may be explained by a decrease in efflux of pyrilamine from the heart of *jvs* mice. To investigate whether or not the difference between wild-type and *jvs* mice was due to a carrier-mediated system, we then examined the influence of an excess concentration (20 mM) of pyrilamine, carnitine, or H₁ antagonists and of a lower temperature (4°C). For this purpose, the accumulation of pyrilamine was determined after 120 min incubation, when the difference between wild-type and *jvs* mice was clear (Fig. 2a). Disappearance of the difference between the two strains in the presence of an inhibitor would suggest inhibition of the efflux process of pyrilamine, whereas a decrease in the absolute value of pyrilamine accumulation in the presence of the inhibitor would indicate inhibition of the influx process and/or tissue binding. The difference in the accumulation of pyrilamine was diminished at 4°C. (Fig. 3a). At 20 mM pyrilamine, the difference in accumulation between wild-type and *jvs* mice was reduced compared with the control (2 μM pyrilamine), but there was still a significant difference (Fig. 3a). The absolute value of the pyrilamine accumulation was also reduced in both strains (Fig. 3a). The significant difference in pyrilamine accumulation between wild-type and *jvs* mice also

disappeared in the presence of 20 mM carnitine (Fig. 3a). The concentration of pyrillamine and carnitine (20 mM) was set as higher as possible so that saturation and/or inhibition can be observed in the pyrillamine accumulation (Fig. 3a). The osmotic control was not used in combination with this study, and it would be possible that the osmotic pressure may affect the membrane transporters. Next, we examined the influence of various antihistamines on the pyrillamine accumulation for 120 min in heart slices. Due to limited solubility, the concentration of ebastine, astemizol and terfenadine was set to be 50 μ M, whereas the concentration of highly soluble diphenhydramine was set at 5 mM (Fig. 3b). Diphenhydramine, promethazine, ebastine and carebastine also diminished the difference in pyrillamine accumulation between wild-type and *jvs* mice (Fig. 3b). Cyproheptadine, diphenhydramine and promethazine also decreased the absolute value of pyrillamine accumulation in both strains, whereas promethazine did not (Fig. 3b). The pyrillamine accumulation by heart slices of *jvs* mice was significantly different from that in wild-type mice even in the presence of cyproheptadine, astemizol, terfenadine and fexofenadine (Fig. 3b).

Renal handling of pyrillamine in wild-type and *jvs* mice

To investigate renal transport of pyrillamine, uptake studies were performed in isolated kidney slices. Uptake of pyrillamine in kidney slices of wild-type mice gradually increased,

whereas the increase in *jvs* mice was much smaller (Fig. 4a). The initial uptake of pyrilamine assessed in kidney slices of wild-type mice for 10 min was saturable (Fig. 4b), and kinetic analysis revealed saturable and unsaturable components with K_m of $236 \pm 165 \mu\text{M}$, V_{max} of $1.62 \pm 0.96 \text{ nmol/mg tissue/10 min}$ and K_{ns} of $1.91 \pm 0.40 \mu\text{L/mg tissue/10 min}$.

Initial uptake of pyrilamine in kidney slices of wild-type mice was reduced to 15 and 34% of the control in the presence of 20 mM pyrilamine and at 4°C, respectively (Fig. 5a). The uptake after preincubation with ATP depletors (10 mM NaN_3 plus 10 mM NaF) for 15 min was 64% of the control (Fig. 5a). Thus, the uptake is temperature- and energy-dependent. On the other hand, 1 mM carnitine had only a minimal effect on pyrilamine uptake in kidney slices (Fig. 5a). To further characterize the influx process of pyrilamine, the effect of antihistamines was also examined in kidney slices. The pyrilamine uptake was significantly inhibited by diphenhydramine, cyptoheptadine, astemizole, ebastine, terfenadine and carebastine, but less so by fexofenadine (Fig. 5b). The effect of typical substrates of renal transporters on pyrilamine uptake was also examined, but tetraethylammonium (TEA), para-aminohippurate (PAH), benzylpenicillin (PCG) and digoxin minimally affected the pyrilamine uptake (Fig. 5c).

DISCUSSION

Although many *in vitro* studies have indicated that OCTN2 is a drug transporter with broad substrate specificity, *in vivo* evidence of its role is quite limited. In the present study, we aimed to clarify the role of OCNT2 in the disposition of an H₁ antagonist, pyrilamine, *in vivo*. When the tissue distribution of pyrilamine was compared between wild-type and *jvs* mice, the K_p values in heart and pancreas were found to be increased, whereas those in kidney and testis were decreased, as a result of the deficiency of *octn2* gene (Table 1), although systemic exposure to pyrilamine was similar in the two strains (Fig. 1a). The *jvs* mice have a hereditary mutation in the *octn2* gene, resulting in functional deficiency of the *octn2* gene product [3-6]. Therefore, the present findings indicate that the tissue distribution of pyrilamine is influenced by *octn2* gene deficiency. We have previously demonstrated that the K_p values of TEA in brain, lung, liver and spleen of *jvs* mice were lower than those in wild-type mice [11]. Similarly, the K_p values of carnitine was also lower in several organs of *jvs* mice [7]. Since TEA and carnitine are substrates of OCTN2 [11,12], and OCTN2 is ubiquitously expressed in many organs [27], OCTN2 may function as an influx transporter in these organs. Pyrilamine is also a substrate of OCTN2 [11,12], but the change in K_p values of pyrilamine associated with *octn2* gene deficiency was different from those for TEA and carnitine, and was tissue-dependent. For example, the K_p of carnitine in heart and pancreas of *jvs* mice was lower than that in wild-type mice [7], whereas the K_p of

pyrilamine in *jvs* mice was higher (Table 1). Therefore, the molecular mechanism(s) of the *octn2* gene-associated change in tissue distribution of pyrilamine should be carefully considered.

The K_p value is generally affected by several kinetic parameters, including unbound fraction in plasma and tissues, and permeability clearance for influx and efflux processes. The unbound fraction in plasma of pyrilamine was similar in wild-type and *jvs* mice (see Results). Therefore, OCTN2 might be either directly or indirectly involved in tissue binding and/or membrane permeation. The K_p of pyrilamine in heart of *jvs* mice was significantly higher than that in wild-type mice 30 min after injection, but the difference was not so marked at 1 min after injection (Table 1). This result was confirmed in uptake studies with heart slices: the difference in pyrilamine accumulation in heart slices between wild-type and *jvs* mice was more marked at 60 min and later after the start of incubation (Fig. 2a). In addition, after preloading pyrilamine into heart slices, efflux of pyrilamine from the heart slices was delayed in *jvs* mice, compared with wild-type mice (Fig. 2b). These kinetic data obtained both *in vivo* and *in vitro* may suggest that OCTN2 functions as an efflux transporter for pyrilamine in heart. This hypothesis is further supported by the recent observation that OCTN2 is localized at plasma membrane of cardiac muscle cells in mice [23] and vascular endothelium in human heart [28]. In addition, the greater accumulation of pyrilamine in heart slices of *jvs* mice, compared with wild-type mice, was decreased or diminished in the presence of 20 mM pyrilamine, carnitine or several H_1

antihistamines (Fig. 3). The higher accumulation of pyrilamine in *jvs* mice was also diminished at 4°C, at which active transport systems show minimal activity (Fig. 3a). These findings can also be explained if we consider the existence of an efflux transporter for pyrilamine which is saturable, sensitive to carnitine and several antihistamines, and temperature-dependent. However, the absolute values of pyrilamine accumulation were also decreased under various conditions (Fig. 3), and a possible effect on tissue binding and/or influx of pyrilamine cannot be excluded. In addition, carnitine failed to inhibit the pyrilamine accumulation in heart slices, whereas the difference of pyrilamine accumulation between wild-type and *jvs* mice was diminished in the presence of excessive carnitine (Fig. 3a). If we consider that carnitine is a good substrate for OCTN2, it would be possible that other unknown pyrilamine transporter than OCTN2 may play a role in the influx of pyrilamine.

Despite the previous observations indicating OCTN2-mediated transport of therapeutic agents *in vitro* [12-14], the present finding is the first to suggest the role of OCTN2 in drug disposition to the heart *in vivo*. There are quite few studies dealing with the pharmacokinetic role(s) of transporters in the heart *in vivo*. Zwart *et al.* demonstrated that distribution of MPP to the heart was decreased in organic cation transporter (OCT) 3 gene knockout mice, proposing that OCT3 is functionally expressed in heart as an influx transporter [29]. Higher levels of distribution to the heart of vinblastine and [¹⁴C]grepafloxacin in gene knockout mice for

multidrug resistance protein 1 and multidrug resistance-associated protein (Mrp) 1, respectively, were also reported, suggesting that P-glycoprotein and Mrp1 function as efflux transporters in the heart [30,31]. In the present study, we also examined the effect of various H₁ antihistamines on pyrilamine accumulation in heart slices (Fig. 3). Among H₁ antagonists, diphenhydramine, promethadine, ebastine and carebastine diminished the difference in pyrilamine accumulation between wild-type and *jvs* mice (Fig. 3b), whereas astemizole and terfenadine, both of which are known to block rapid delayed rectifier K⁺ current, leading to QT prolongation in the heart [21,22], had minimal effects on pyrilamine accumulation (Fig. 3b). The efflux transporter would affect unbound drug concentration in the heart tissue, which is primarily important for K⁺ channel inhibition. Therefore, further toxicological studies focusing on the role of OCTN2 and other transporters in the disposition of H₁ antihistamines in heart are needed.

The mechanism of the difference in K_p value of the kidney between wild-type and *jvs* mice is likely to be more complicated. The lower K_p value in the kidney of *jvs* mice (Table 1) suggests that the reduction in urinary excretion in *jvs* mice (Fig. 1b) may be attributable to decreased uptake in renal epithelial cells. This hypothesis would be compatible with the present finding that a lower K_p value in *jvs* mice was observed within a short period (~1 min) after pyrilamine injection (Table 1), and that the uptake of pyrilamine in isolated kidney slices of *jvs* mice was also lower than that of wild-type mice (Fig. 4a). Thus, the uptake of pyrilamine, which

presumably occurs at the basolateral membrane, was reduced in *jvs* mice. On the other hand, immunohistochemical study has revealed that OCTN2 is localized on the brush-border membrane of renal proximal cells [10]. Therefore, certain transporter(s) directly or indirectly associated with OCTN2 may be involved in pyrilamine uptake at the basolateral membrane. Uptake studies with kidney slices have shown that the pyrilamine transporter on the basolateral membrane is not influenced by inhibitors of known basolateral membrane transporters, such as OCTs, organic anion transporters and organic anion transporting polypeptides (Fig. 5c). The uptake transporter has high affinity for pyrilamine, with K_m of 236 μM (Fig. 4b), and is strongly inhibited by cyproheptadine, astemizole and ebastine (Fig. 5b), all of which mainly exist as cationic forms at physiological pH. These characteristics are similar to those of the pyrilamine uptake system previously observed in brain capillary endothelial cells [32-35].

OCTN2 is localized on apical membranes of renal proximal tubules and involved in renal tubular secretion of TEA [11]. Our recent study has also revealed that cephaloridine is secreted into urine by OCTN2 [16]. Consequently, it is possible that OCTN2 is also involved in pyrilamine secretion at apical membrane of renal epithelial cells. However, reduction in both urinary excretion of pyrilamine and K_p value for kidney (~ 1 min) in *jvs* mice (Fig. 1b, Table 1) indicates that renal secretion of pyrilamine at apical membrane is not rate limiting step. Thus, the involvement of OCTN2 in pyrilamine secretion at apical membrane could not be demonstrated in

the present study.

Pyrilamine is highly distributed to the brain (K_p value of 12 ~ 14; Table 1). Although we could not demonstrate that OCTN2 is the pyrilamine transporter in the brain in the present study, the K_p value in the brain of *jvs* mice tended to be higher than that in wild-type mice (Table 1), suggesting that OCTN2 may be involved in pyrilamine distribution to the brain. Recently, Okura *et al.* have reported that oxycodone, a weak cationic drug and an opioid agonist used for treatment of moderate to severe cancer pain, is transported into the brain partially via the pyrilamine transporter [34]. Because these transporters presumably localized at the blood-brain barrier would affect unbound drug concentration inside the brain, it is essential to identify the pyrilamine transporter in order to understand the mechanism of sedation by H₁ antagonists and the efficacy of drugs targeting the central nervous system.

Regarding the tissue distribution of carnitine, significant difference of its K_p values between wild-type and *jvs* mice was observed in many tissues, and this was compatible to expression profile of OCTN2 in ubiquitous tissues [7, 27]. In the present study, however, the alteration of pyrilamine K_p values in *jvs* mice was observed only in heart, pancreas, kidney and testis. This may be because other transporter(s) than OCTN2 would be involved in the tissue distribution of pyrilamine. We have previously reported that pyrilamine is efficiently taken up into brain via saturable transport system [32, 33, 35]. This “pyrilamine transporter” is probably

different from OCTN2 because of to the difference in transport characteristics such as Na⁺- and pH dependency [34]. If the contribution of other transporter(s) to overall tissue distribution of pyrilamine is higher than that of OCTN2, the involvement of OCTN2 in tissue distribution of pyrilamine would not be observed, leading to discrepancy between the alteration of K_p values and expression of OCTN2. Therefore, OCTN2 would be one of the transporters involved in tissue distribution of pyrilamine.

CONCLUSION

in vivo and *in vitro* pharmacokinetic studies revealed that OCTN2 is involved in pyrilamine distribution to at least heart and kidney. This is the first evidence that OCTN2 may act as an efflux transporter for therapeutic agents in the heart *in vivo*. Further studies are needed to clarify the role of OCTN2 in the heart to understand its toxicological relevance, and *jvs* mice may be a helpful tool for this purpose.

ACKNOWLEDGEMENT

We thank Ms Lica Ishida for technical assistance.

REFERENCE

- 1 Wu X, Prasad PD, Leibach FH, Ganapathy V. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. *Biochem Biophys Res Commun* 1998; **246**: 589-595.
- 2 Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A. Molecular and Functional Identification of Sodium Ion-dependent, High Affinity Human Carnitine Transporter OCTN2. *J Biol Chem* 1998; **273**: 20378-20382.
- 3 Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, Nikaido H, Sai Y, Koizumi A, Shoji Y, Takada G, Matsuishi T, Yoshino M, Kato H, Ohura T, Tsujimoto G, Hayakawa J, Shimane M, Tsuji A. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. *Nat Genet* 1999; **21**: 91-94.
- 4 Hashimoto N, Suzuki F, Tamai I, Nikaido H, Kuwajima M, Hayakawa J, Tsuji A. Gene-dose effect on carnitine transport activity in embryonic fibroblasts of *JVS* mice as a model of human carnitine transporter deficiency. *Biochem Pharmacol* 1998; **55**: 1729-1732.
- 5 Lu K, Nishimori H, Nakamura Y, Shima K, Kuwajima M. A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. *Biochem Biophys Res Commun* 1998; **252**: 590-594.
- 6 Yokogawa K, Miya K, Tamai I, Higashi Y, Nomura M, Miyamoto K, Tsuji A. Characteristics of

L-carnitine transport in cultured human hepatoma HLF cells. *J Pharm Pharmacol* 1999;

51: 935-940

7 Yokogawa K, Higashi Y, Tamai I, Nomura M, Hashimoto N, Nikaido H, Hayakawa J,

Miyamoto K, Tsuji A. Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. *J Pharmacol Exp Ther* 1999; **289**: 224-230.

8 Yokogawa K, Yonekawa M, Tamai I, Ohashi R, Tatsumi Y, Higashi Y, Nomura M, Hashimoto N,

Nikaido H, Hayakawa J, Nezu J, Oku A, Shimane M, Miyamoto K, Tsuji A. Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. *Hepatology* 1999; **30**: 997-1001

9 Kato Y, Sugiura M, Sugiura T, Wakayama T, Kubo Y, Kobayashi D, Sai Y, Tamai I, Iseki S,

Tsuji A. Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. *Mol Pharmacol* 2006; **70**: 829-83720

10 Tamai I, Nakanishi T, Kobayashi D, China K, Kosugi Y, Nezu J, Sai Y, Tsuji A. Involvement

of OCTN1 (SLC22A4) in pH-Dependent Transport of Organic Cations. *Mol Pharm* 2003; **1**: 57-66

11 Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A.

Molecular and physiological evidence for multifunctionality of carnitine/organic cation

- transporter OCTN2. *Mol Pharmacol* 2001; **59**: 358-366.
- 12 Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. *J Pharmacol Exp Ther* 1999; **291**: 778-784.
- 13 Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. *J Pharmacol Exp Ther* 1999; **290**: 1482-1492.
- 14 Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V. bactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. *J Biol Chem* 2000; **275**: 1699-1707
- 15 Grigat S, Fork C, Bach M, Golz S, Geerts A, Schoming E and Grundemann D. The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate. *Drug Metab Dispos* 2008; in press.
- 16 Kano T, Kato Y, Ito K, Ogihara T, Kubo Y, Tsuji A. Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephalexin in mice. *Drug Metab Dispos*.2008; in press.
- 17 Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashita T, Moritani S, Tsuruo T,

- Yamashita J. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. *Life Sci* 1992; **51**: 1427-1437.
- 18 Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. Disruption of the mouse *mdr1a* P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. *Cell* 1994; **20**: 491-502.
- 19 Tamai I, Kido Y, Yamashita J, Sai Y, Tsuji A. Blood-brain barrier transport of H₁-antagonist ebastine and its metabolite carebastine. *J Drug Target* 2000; **8**: 383-393.
- 20 Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H₁-antagonists. *Drug Metab Dispos* 2003; **31**: 312-318.
- 21 Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. *Proc Natl Acad Sci U S A*. 2000; **97**:12329-12333
- 22 García-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stühmer W, Pardo LA. Mechanism of block of hEag1 K⁺ channels by imipramine and astemizole. *J Gen Physiol* 2004; **124**: 301-317.
- 23 Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S, Tsuji A. Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. *Drug Metab Pharmacokinet* 2008; **23**:207-215

- 24 Koizumi T, Nikaido H, Hayakawa J, Nonomura A, Yoneda T. Infantile disease with microvesicular fatty infiltration of viscera spontaneously occurring in the C3H-H-2(0) strain of mouse with similarities to Reye's syndrome. *Lab Anim* 1988; **22**: 83-87
- 25 Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. *J Pharmacobiodyn* 1981; **4**: 879 – 885.
- 26 Kelly DW, Slikker W Jr. The metabolism and elimination of pyrilamine maleate in the rat. *Drug Metab Dispos* 1987; **15**: 460-465
- 27 Tamai I, Ohashi R, Nezu JI, Sai Y, Kobayashi D, Oku A, Shimane M, Tsuji A. Molecular and functional characterization of organic cation/carnitine transporter family in mice. *J Biol Chem* 2000; **275**: 40064-40072.
- 28 Grube M, Meyer zu Schwabedissen HE, Präger D, Haney J, Möritz KU, Meissner K, Roskopf D, Eckel L, Böhm M, Jedlitschky G, Kroemer HK. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). *Circulation* 2006; **113**: 1114-1122.
- 29 Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. *Mol Cell Biol* 2001; **21**: 4188-4196.
- 30 van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. Altered

pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. *J Natl Cancer Inst* 1996; **88**: 994-949

31 Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. *J Pharmacol Exp Ther* 2004; **310**: 648-655.

32 Yamazaki M, Fukuoka H, Nagata O, Kato H, Ito Y, Terasaki T, Tsuji A. Transport mechanism of an H₁-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. *Biol Pharm Bull* 1994; **17**: 676-679.

33 Yamazaki M, Terasaki T, Yoshioka K, Nagata O, Kato H, Ito Y, Tsuji A. Carrier-mediated transport of H₁-antagonist at the blood-brain barrier: a common transport system of H₁-antagonists and lipophilic basic drugs. *Pharm Res* 1994; **11**: 1516-1518

34 Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y. Involvement of the Pyrilamine Transporter, a Putative Organic Cation Transporter, in Blood-Brain Barrier Transport of Oxycodone. *Drug Metab Dispos* 2008; **36**: 2005-2013

35 Yamazaki M, Terasaki T, Yoshioka K, Nagata O, Kato H, Ito Y, Tsuji A. Carrier-mediated transport of H₁-antagonist at the blood-brain barrier: mepyramine uptake into bovine brain capillary endothelial cells in primary monolayer cultures. *Pharm Res* 1994; **11**: 975-978.

LEGENDS TO FIGURES

Figure 1

Plasma concentration (A) and cumulative urinary excretion (B) of pyrilamine

Pyrilamine was intravenously administered at a dose of 3.75 mg/kg to wild-type (open circles) and *jvs* (closed circles) mice. Data are expressed as mean \pm S.E.M (n = 3-8). Where an error bar is not shown, it is smaller than the symbol.

Figure 2

Time-dependent uptake (A) and efflux (B) of pyrilamine in isolated heart slices

(A) Uptake of pyrilamine in heart slices of wild-type (open circles) and *jvs* mice (closed circles) was measured during incubation with pyrilamine (2 μ M) at 37°C. (B) Heart slices of wild-type (open circles) and *jvs* mice (closed circles) were pre-incubated with 2 μ M pyrilamine for 60 min, washed with ice-cold buffer, and incubated at 37°C in the absence of pyrilamine for the indicated periods. Data represent amount of pyrilamine remaining in the slices, normalized by the amount just after the pre-incubation, and are expressed as mean \pm S.E.M. (n = 3-4). Where an error bar is not shown, it is smaller than the symbol. * p <0.05

Figure 3

Effect of temperature, carnitine and antihistamines on accumulation of pyrilamine in isolated heart slices

(A) Accumulation of pyrilamine (2 μM) in heart slices of wild-type (open bars) and *jvs* mice (closed bars) was measured at 37°C for 120 min, at which time, the accumulated amount was close to the steady-state value (see Fig. 2), in the presence of 20 mM pyrilamine or carnitine, or at 4°C. (B) The accumulation of pyrilamine (2 μM) in heart slices of wild-type (open bars) and *jvs* mice (closed bars) was measured for 120 min at 37°C in the presence or absence of antihistamines at designated concentrations. Data are expressed as mean \pm S.E.M. (n = 3-4).

Where an error bar is not shown, it is smaller than the symbol. * $p < 0.05$

Figure 4

Time course (A) and concentration dependence (B) of the uptake of pyrilamine in isolated kidney slices

(A) The uptake of pyrilamine (2 μM) in kidney slices of wild-type (open circles) and *jvs* mice (closed circles) was measured at 37°C. (B) The uptake of pyrilamine at various concentrations in kidney slices of wild-type mice was measured for 10 min at 37°C. The pyrilamine concentrations were set to be 30, 50, 100, 300, 500, 750, 1000, 3000, 5000, 10000 and 20000 μM . Data are presented as an Eadie-Hofstee plot and expressed as mean \pm S.E.M. (n = 3-4). Where an error bar

is not shown, it is smaller than the symbol. * $p < 0.05$

Figure 5

Effect of temperature and carnitine (A), transporter substrates (B) and antihistamines (C)

on pyrilamine uptake in isolated kidney slices

Uptake of pyrilamine (2 μM) in kidney slices of wild-type mice was measured at 37°C for 10 min in the presence or absence of each compound at the designated concentration. In panel (A), the incubation was also performed at 4°C. Data are expressed as mean \pm S.E.M. (n = 3-4). Where an error bar is not shown, it is smaller than the symbol. * $p < 0.05$

Table 1**Values of tissue-to-plasma concentration ratio (Kp) of pyrilamine in wild-type and *jvs* mice^a**

	Wild-type		<i>jvs</i>	
	Kp (30 min) ^b			
Brain	11.8	± 0.8	14.3	± 1.1
Fat	7.11	± 0.46	7.65	± 0.87
Heart	6.01	± 0.44	10.6	± 1.1 ^d
Intestine	0.432	± 0.154	1.68	± 0.82
Kidney	88.2	± 17.8	13.8	± 3.2 ^d
Lung	24.7	± 1.5	18.9	± 2.1
Pancreas	26.7	± 1.0	40.7	± 6.9 ^d
Spleen	35.1	± 2.8	32.4	± 4.8
Testis	20.2	± 1.1	13.1	± 2.0 ^d


Kp (1 min) ^c				
Heart	34.1	± 3.4	43.9	± 5.5
Kidney	43.3	± 4.6	24.4	± 2.8 ^d


^a Data were expressed as mean ± S.E.M (n = 4-6)


^b The Kp values were measured at 30 min after intravenous administration of pyrilamine at a dose of 3.75 mg/kg.

^c The Kp values were measured at 1 min after intravenous administration of pyrilamine at a dose of 3.75 mg/kg.


^d Significantly different from wild-type mice. $p < 0.05$









(b)








(b)



A







(b)

